NewAmsterdam Pharma reports Q2 revenue $19.145M vs $2.279M last year

“Fueled by strong momentum in the first half of 2025, obicetrapib is rapidly advancing towards patients worldwide, potentially addressing the urgent need for additional cardiovascular disease treatment options,” said Michael Davidson, M.D., Chief Executive Officer of NewAmsterdam. “We continue to see compelling data from our Phase 3 studies, not only reinforcing obicetrapib’s observed lipoprotein modifying properties including robust LDL-C reduction but also suggesting a potential role in reducing neurodegenerative risk. Most recently, we announced positive data from a prespecified Alzheimer’s disease biomarker analysis in the BROADWAY trial. Over a 12-month period, key plasma markers associated with Alzheimer’s pathology were observed to be lower in patients with atherosclerotic cardiovascular disease who received obicetrapib compared to those who received placebo. These findings point to the possibility that obicetrapib may address the converging pathways of cardiovascular and neurovascular disease with a single, oral therapy.”